SI-BONE, Inc. Beats Consensus Estimates as Q3 Revenue Rises 14.5%

SI-BONE, Inc. beat consensus estimates for revenue and per-share loss in the third quarter, as worldwide revenue grew 14.5% year over year to $55.704 million for the period ended Sept. 30. The company announced the results Monday, Nov. 2.

Revenue rose from $48.656 million in the year-earlier quarter. SI-BONE recorded a GAAP net loss of $3.620 million, or $0.08 per share, compared with a $4.566 million loss, or $0.11 per share, a year earlier.

Revenue exceeded the listed consensus estimate of $55.31 million by $394,000. The $0.08-per-share loss was 4.64 cents narrower than the listed estimate of $0.1264 per share. Consensus calculations can vary among estimate providers, so these comparisons use the listed figures.

Domestic sales grew 13.9% to $52.8 million; overseas sales advanced 27% to $2.9 million. SI-BONE makes products for procedures involving compromised bone.

The company reaffirmed its 2026 revenue outlook of $231 million to $233 million and gross-margin outlook of about 79%. It lowered its expected operating-expense growth at the revenue midpoint to about 10.5%, compared with about 12% previously, and maintained its expectation for positive adjusted EBITDA.

The financial statements accompanying the results were unaudited.

“Robust third-quarter growth in procedure volumes and active physicians underscores rising demand for our diversified and differentiated platform technologies,” CEO Laura Francis said.